Cost-Utility Analysis of the Treatment With Ataluren Plus Standard of Care Compared With Standard of Care Alone in Patients With Duchenne Muscular Dystrophy in Brazil

Read full text Summarise with VIRAT
Authors: Eliane Würdig Roesch, Verônica Colpani, Grace Anne Azevedo Dória, Klébya Hellen Dantas de Oliveira, Cátia Cristina Martins de Oliveira, Henry Maia Peixoto, Ana Flávia de Morais Oliveira
Cited by: 0
References: 41

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVES: to evaluate the cost-utility of ataluren plus standard of care (SoC) for treating patients with nonsense mutation Duchenne muscular dystrophy from the Brazilian public health system perspective. METHODS: A semi-Markov model, comprising 5 states, was developed to estimate the incremental cost per quality-adjusted life-years (QALYs) of ataluren plus SoC compared with SoC alone. A 48-year time horizon was used in the base-case analysis, considering annual cycles. Costs were expressed as international dollars (Int$) applying the purchasing power parity conversion rate (Brazilian purchasing power parity of 2.44 BRL/Int$ in 2023). The transition probabilities and utility data were obtained from previous studies, and costs were based on data from a microcosting study and the Brazilian Drug Market Regulation Chamber. Both costs and QALYs were discounted using a rate of 5%. Parameter uncertainty was assessed through deterministic and probabilistic sensitivity analyses. RESULTS: Ataluren plus SoC leads to incremental 0.503 QALYs and incremental costs of Int$13 298 877.45, resulting in an incremental cost-utility ratio of Int$26 415 910.08/QALY. According to the deterministic sensitivity analysis, utilities related to the state's health progression of the model were the parameter that most significantly influenced the incremental cost-utility ratio. In the probabilistic sensitivity analysis, all estimates were above the current willingness-to-pay threshold of Int$49 180.33 per QALY for rare diseases. CONCLUSIONS: Ataluren plus SoC for treating nonsense mutation Duchenne muscular dystrophy patients was not a cost-effective intervention compared with SoC alone from the perspective of the Brazilian public health system.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Pharmaceutical Economics and Policy Neurogenetic and Muscular Disorders Research

Publication details

Journal / source
Value in Health Regional Issues
Volume
56
Pages
101623–101623
Publication date
26 March 2026
Language
EN